Themis Medicare Limited

THEMISMED

INE083B01024

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:48 2024-04-30 am EDT			5-day change	1st Jan Change
220.4 ^INR	-2.33%		+6.27%	+3.52%

Feb. 10	Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Themis Medicare Limited Launches REMITHEM	CI

Themis Medicare Limited Declares Dividend for the Financial Year Ended March 31, 2022

September 20, 2022 at 02:50 am EDT

Themis Medicare Limited at the AGM, the shareholders approved to declare a dividend of INR 5.00 per equity share of INR 10 each for the financial year ended March 31, 2022.

Latest news about Themis Medicare Limited

Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 10	CI
Themis Medicare Limited Launches REMITHEM	Nov. 10	CI
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 04	CI
Themis Medicare Limited Announces Incorporation of Wholly Owned Subsidiary	23-09-20	CI
Themis Medicare Limited Announces Cessation of Vijay Agarwal as Independent Director	23-09-09	CI
Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023	23-09-07	CI
Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-13	CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-13	CI
Themis Medicare Limited Recommends Dividend for Financial Year Ended 31 March 2023	23-05-13	CI
Themis Medicare Limited Announces Board Resignations	23-05-02	CI
Themis Medicare Gets Drug Controller General of India’s No-Objection for Diclofenac Injection	23-02-17	MT
Themis Medicare Announces DCGI Approval of Remifentanil Hydrochloride 1mg/2mg for Injection for Import and Marketing	23-02-17	CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-03	CI
Themis Medicare Launches Drug for Treatment of Menopausal Symptoms in India	23-01-03	MT
Themis Medicare Ltd. Launches Lenzetto Â¡Global Brand of Estradiol Novel Drug Delivery System	23-01-03	CI
Themis Medicare Posts Decline in Fiscal Q2 Consolidated Profit	22-11-08	MT
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-07	CI
Themis Medicare Limited entered into share purchase agreement to acquire additional 6.47% stake in Gujarat Themis Biosyn Limited from Pharmaceutical Business Group Limited for approximately INR 700 million.	22-11-06	CI
Themis Medicare Partners with NFL Biosciences to Develop Anti-Smoking Drug in India	22-10-06	MT
NFL Biosciences Partners with Themis Medicare for the Development of NFL-101 in India	22-10-05	CI
Themis Medicare Limited Informs the Second Term of Office of Mr. Hoshang Sinor as Independent Director, Come to End	22-09-20	CI
Themis Medicare Limited Declares Dividend for the Financial Year Ended March 31, 2022	22-09-20	CI
Themis Medicare Limited Announces Resignation of Lajos Kovacs as Board of Directors	22-09-07	CI
Themis Medicare's Consolidated Profit Plummets in Fiscal Q1	22-07-28	MT

Themis Medicare Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
THEMIS MEDICARE LIMITED	+3.52%	249M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.27%	43.75B
OTSUKA HOLDINGS CO., LTD.	+27.47%	22.06B
SANDOZ GROUP AG	+15.11%	14.46B
CIPLA LIMITED	+12.33%	13.62B
ZYDUS LIFESCIENCES LIMITED	+38.36%	11.61B
ONO PHARMACEUTICAL CO., LTD.	-9.54%	6.9B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.32B